| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2019: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2018: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
We established a panel of anti-idiotype antibodies against the HIV neutralizing antibodies such as V3 antibody (1C10) and CD4i antibodies (4E9C, 916B2). B cells recognized by these anti-idiotype antibodies are obtained from the peripheral blood of HIV-infected cases by single cell sorting, and their biological activities are under investigation. In addition, in the analysis using 5 anti-idiotype antibodies against 1C10, # 102-reactive cells were found in the early stage of infection, # 87 in the middle stage of infection, # 103 in the late stage of infection were found. In the case of # 92 the binding cells were found in the early to middle stage, and #103 cells that bound in the middle to late stages were observed. These data suggest the stepwise induction of neutralizing antibody-producing B cells with multiple anti-idiotype antibodies.
|
